NEW YORK (GenomeWeb) – Pathology Associates Medical Laboratories (PAML) today announced that it has entered into a collaboration with Axela to develop multiplex assays to detect patient immunity to diseases that can be prevented with vaccines.
The serologic assays will measure antibodies to a wide range of viruses including measles, mumps, and rubella to help determine a patient's immunity to those diseases. The terms of the agreement also call for multiplex targets beyond the initial serological assays.
"Having access to rapid, sensitive, and highly multiplexed assays will allow us to economically target emerging customer needs such as the recent focus on verifying proper immunization," PAML CEO Francisco Velázquez said in a statement.
Toronto-based Axela is a molecular diagnostics firm specializing in flow-through microarrays, detection strategies, and assay development.
Financial terms of the agreement were not disclosed.